BIRKERØD, DENMARK—ViroGates A/S (“ViroGates” or the “Company”), a medical technology company developing blood tests for measuring chronic inflammation at health clinics and hospitals, today publishes the financial calendar for 2026 with the following key dates:

The interim and annual financial reports will be available on ViroGates’ website (www.virogates.com) immediately after release.

ViroGates encourages all shareholders to sign up to receive relevant shareholder information on its shareholder portal.

Written requests to have specific business transacted at the Annual General Meeting will be included in the agenda if received by the company no later than 2nd April 2026 via email to jk@virogates.com or jbj@virogates.com.

For further information, please contact:
ViroGates A/S:
CEO, Jakob Knudsen
Tel. (+45) 2226 1355, email: jk@virogates.com

Certified Advisor:
Västra Hamnen Corporate Finance AB
Per Lönn
Tel. (+46) 40 200 250 | Email: per.lonn@vhcorp.se

About ViroGates
ViroGates A/S is an international medical technology company that develops and markets blood tests to measure chronic inflammation at health clinics and hospitals. ViroGates markets its blood test products under the suPARnostic® brand.

The company was founded in 2000. Headquartered in Denmark, ViroGates’ sales force covers Spain, France, and Benelux, while distributors serve other markets. ViroGates’ shares (ticker “VIRO”) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.